1. Motonobu Saito, Hiroyuki Suzuki, Koji Kono, Seiichi Takenoshita, Takashi Kohno. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surgery Today. 48(1):1-8, 2018

 

2. Takumi Yamaura, Junji Ezaki, Naoyuki Okabe, Hironori Takagi, Yuki Ozaki, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Satoshi Muto, Yuki Matsumura, Takeo Hasegawa, Mika Hoshino, Jun Osugi, Yutaka Shio, Satoshi Waguri, Hirosumi Tamura, Jun-ichi Imai, Emi Ito, Yuka Yanagisawa, Reiko Honma, Shinya Watanabe, Hiroyuki Suzuki. Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. Oncology Letters. 15(2):1549-1558, 2018

 

3. Motonobu Saito, Katsuharu Saito, Kouya Shiraishi, Daichi Maeda, Hiroyuki Suzuki, Yoshihiro Minamiya, Koji Kono, Takashi Kohno, Akiteru Goto. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Molecular and Clinical Oncology. 8(2):310-314, 2018

 

4. Motoyasu Sagawa, Hiroyuki Oizumi, Hiroyuki Suzuki, Hidetaka Uramoto, Katsuo Usuda, Akira Sakurada, Masayuki Chida, Satoshi Shiono, Jiro Abe, Tohru Hasumi , Masami Sato, Nobuyuki Sato, Jotaro Shibuya, Hiroyuki Deguchi, Yoshinori Okada. A prospective 5-year follow-up study after limited resection for lung cancer with ground-glass opacity. European Journal of Cardio-thoracic Surgery. 53(4):849-856, 2018

 

5. Mitsunori Higuchi, Hironori Takagi, Yuki Ozaki, Takuya Inoue, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Yutaka Shio, Hiroyuki Suzuki. Comparison of surgical outcomes after pneumonectomy and pulmonary function-preserving surgery for non-small cell lung cancer. Fukushima Journal of Medical Science. 64(1):30-37, 2018

 

6. Yuki Owada-Ozaki, Yuki Matsumura, Hiroyuki Suzuki. VV-ECMO during subsequent segmentectomy after right pneumonectomy. Journal of Surgical Case Reports. 2018(2): rjy213, 2018

 

7. Korehito Kashiwagi, Mai Yanagida, Daiki Matsui, Mizuko Tanaka, Kotaro Sugimoto, Honglei Chen, Naoki Ichikawa-Tomikawa, Shigeru Marubashi, Hiroyuki Suzuki, Hideki Chiba. Expression of liver X receptors in normal and refractory carcinoma tissues of the human lung and pancreas. Histology and Histopathology. 33(5):497-505, 2018

 

8. Kazuki Hayasaka, Satoshi Shiono, Yuki Matsumura, Naoki Yanagawa, Hiroyuki Suzuki, Jiro Abe, Motoyasu Sagawa, Akira Sakurada, Masato Katahira, Satomi Takahashi, Makoto Endoh, Yoshinori Okada. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma. Annals of Thoracic Surgery. 105(6):1648-1654, 2018

 

9. Kazuyoshi Takeda, Kazutaka Kitaura, Ryuji Suzuki, Yuki Owada, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Takuya Tsunoda, Ko Okumura, Hiroyuki Suzuki. Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination. Cancer Immunology, Immunotherapy. 67(6):949-964, 2018

 

10. Motonobu Saito, Kouya Shiraishi, Akiteru Goto, Hiroyuki Suzuki, Takashi Kohno, Koji Kono. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. Japanese Journal of Clinical Oncology. 48(7): 603-608, 2018

 

11. Yuki Owada-Ozaki, Satoshi Muto, Hironori Takagi, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Ohsugi, Mika Hoshino, Yutaka Shio, Hideaki Nanamiya, Jun-ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Suzuki. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report. Journal of Thoracic Oncology. 13(8):1217-1221, 2018

 

12. Takumi Yamaura, Hiroyuki Suzuki. Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy. Journal of Thoracic Oncology. 13(10):e209-e210, 2018

 

13. Mitsunori Higuchi, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Tomoko Suzuki, Miwako Saito, Katsunao Niitsuma, Kotaro Endo, Ikuro Oshibe, Nobutoshi Soeta, Takuro Saito, Hiroshi Hojo, Mitsuru Munakata, Hiroyuki Suzuki. Brief report on similar mutational changes in neurofibromatosis type 2 gene in minute pulmonary meningothelial-like nodule and meningioma of the central nervous system. Oncotarget. 9(89): 36012-36016, 2018

 

14. Yuki Matsumura, Yuki Owada-Ozaki, Hiroyuki Suzuki. Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing. Journal of Thoracic Disease. 10(Suppl 33): S4147-S4150, 2018

 

15. 武藤哲史, 鈴木弘行. 特集　腫瘍免疫研究の最前線　非小細胞肺がんに対するがん免疫療法の進歩. 癌と化学療法. 45(2): 212-216, 2018

 

16. 尾崎有紀, 鈴木弘行. 癌免疫　カンファレンスルーム　肺癌から学ぶこと―ガイドラインの変更―. 消化器外科. 41(2): 193-197, 2018

 

17. 鈴木弘行. 肺癌治療の現状と展望. 安達医師会報. 57: 41, 2018

 

18. 鈴木弘行. 編集後記. 肺癌 58 (3): 241, 2018

 

19. 尾崎有紀, 西山恭子, 小林敬広, 錫谷達夫, 鈴木弘行. 特集　免疫腫瘍学(Immuno- Oncology)の夜明け　Immuno-Oncology におけるバイオマーカー検索―腸内環境と免疫チェックポイント阻害薬の関係―. 癌と化学療法. 45(9): 1234-1237, 2018

 

20. 鈴木弘行. 巻頭言　附属病院の経営改善計画について. 福島県立医科大学　大学医師会会報. 139: 1, 2018

 

21. 武藤哲史, 岡部直行, 長谷川剛生, 塩豊, 鈴木弘行. 直腸癌の縦隔リンパ節転移により急性壊死性縦隔炎をきたした1例. 日本呼吸器外科学会雑誌. 32(7): 881-886, 2018

 

22. 樋口光徳, 遠藤浩太郎, 押部郁朗, 添田暢俊, 斎藤拓朗, 鈴木弘行. NF-2遺伝子欠失を有する微小肺髄膜細胞様結節(MPMN)の1例. 肺癌. 58(7): 975-979, 2018